Portola Pharmaceuticals Inc (PTLA)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

270 EAST GRAND AVENUE, SUITE 22 SOUTH SAN FRANCISCO, CA 94080

Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboemboli® prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery.

Data based on most recent fiscal year report
Market Cap2.088 Billion Shares Outstanding65.25 Million Avg Volume1.631 Million
1-Yr BETA vs S&P TR Current Ratio5.94 Quick Ratio5.92
View SEC Filings from PTLA instead.
Q2 2019 All Institutions Hedge Funds 1
To trade PTLA now:
Filers who had this stock in their top 10: 6 3 (0.31%)
13F Filers holding this stock: 193 30 (3.1%)
Aggregate 13F shares on 06/30/2019: 69.973 Million 9.273 Million
Aggregate 13F shares on 03/31/2019: 68.805 Million 10.606 Million
Percent change: 1.70% -12.56%
Funds creating new positions: 29 9
Funds Adding to an existing position: 68 9
Funds closing out their position: 35 11
Funds reducing their position: 53 6
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding PTLA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

5 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

5 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

RENTON HOLLINGS

  • Director
16,020 2019-08-08 3

BIRD JEFFREY W

  • Director
3,876,666 2019-07-22 2

BREGE LAURA

  • Director
0 2019-07-17 1

HOMCY CHARLES J CHAIRMAN OF PHARMACEUTICALS

  • Officer
  • Director
1,361,426 2019-07-01 4

WOLFF HENRY WARD

  • Director
0 2019-06-28 3

STUMP DAVID C

  • Director
0 2019-06-28 1

JOHNSON JOHN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
37,400 2019-06-27 1

GALAKATOS NICHOLAS

  • Director
0 2019-06-19 0

FENTON DENNIS M

  • Director
13,194 2019-06-13 1

LIS WILLIAM

  • Director
0 2019-06-12 0

GARLAND J. SCOTT

  • Director
0 2019-06-06 3

DIER MARDI

  • Director
0 2019-06-05 5

CURNUTTE JOHN T EVP R&D

  • Officer
101,656 2019-05-17 5

CALIFF ROBERT

  • Director
0 2019-05-15 0

MORIARTY JOHN B EVP, GENERAL COUNSEL

  • Officer
39,952 2019-03-04 2

BRAME GLENN P EVP, CTOO

  • Officer
40,000 2019-01-31 1

MEYER ERNIE EVP AND CHRO

  • Officer
48,750 2019-01-31 2

KOENIG SHELDON L. EVP, CHIEF COMMERCIAL OFFICER

  • Officer
25,000 2019-01-31 2

FU TAO EVP, CBO

  • Officer
77,043 2018-08-31 1

MAXWELL (MAURITIUS) PTE LTD

CAIRNHILL INVESTMENTS (MAURITIUS) PTE LTD

FULLERTON MANAGEMENT PTE LTD

TEMASEK HOLDINGS (PRIVATE) LTD

  • 10% Owner
No longer subject to file 2018-05-07 0

LAWRENCE JOHN H III SVP, CHIEF MEDICAL OFFICER

  • Officer
6,875 2018-01-31 0

FULLERTON MANAGEMENT PTE LTD

TEMASEK HOLDINGS (PRIVATE) LTD

  • 10% Owner
6,583,568 2015-12-09 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

RENTON HOLLINGS - Director

2019-08-08 M 5,000 $9.00 a 18,194 16,020.00 direct

RENTON HOLLINGS - Director

2019-08-08 M 5,000 d 10,000 16,020.00 direct

RENTON HOLLINGS - Director

2019-08-08 S 5,000 $30.00 d 13,194 16,020.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments